GABAergic Influences on Medulloblastoma

TL;DR

This paper explores how GABA, a brain chemical, affects medulloblastoma, a common childhood brain tumor, and suggests it could be a potential treatment target.

Contribution

The paper identifies GABRA5 and GABRB1 as novel prognostic markers in medulloblastoma subgroups.

Findings

GABA and GABAA receptor agonists reduce the viability of medulloblastoma cells.

High GABRA5 expression correlates with shorter survival in Group 3 and Group 4 medulloblastoma.

High GABRB1 expression is linked to longer survival across all medulloblastoma subgroups.

Abstract

Medulloblastoma (MB) is the most common malignant brain tumor in children and typically arises in the cerebellum, likely due to disruptions in neuronal precursor development. The primary inhibitory neurotransmitter in the central nervous system (CNS), γ-aminobutyric acid (GABA), exerts its effects through GABAA, GABAB, and GABAC receptors. GABA receptor activity regulates the development and function of cerebellar neurons, including glutamatergic cerebellar granule cells (CGCs). Beyond the nervous system, GABA is also a common metabolite in non-neuronal cell types. An increasing body of evidence indicates that GABA can influence cell proliferation, differentiation, and migration in several types of adult solid tumors, including brain cancers. GABA and GABAA receptor agonists can impair the viability and survival of MB cells, primarily acting on GABAA receptors containing the α5 subunit. A marked expression of the gene encoding the α5 subunit is found across all MB tumor molecular subgroups, particularly Group 3 MB, which has a poor prognosis. Importantly, high levels of the γ-aminobutyric acid type A receptor subunit α5 (GABRA5) gene are associated with shorter patient overall survival in Group 3 and Group 4 MB. In contrast, high γ-aminobutyric acid type A receptor subunit β1 (GABRB1) gene expression is related to longer survival in all MB subgroups. The GABAergic system may, therefore, regulate MB cell function and tumor progression and influence patient prognosis, and is worthy of further investigation as a biomarker and therapeutic target in MB.

Figures